Effect of COVID-19 (SARS-CoV-2) Vaccination on Patients with Atopic Dermatitis Treated with Dupilumab: A Multicenter, Observational Study

다국어 초록 (Multilingual Abstract)

Background: Atopic dermatitis (AD) patients usually wonder if their condition will worsenafter vaccination or if they should continue with the treatment they are receiving. Consideringthat many patients treated with dupilumab had previously experienced severe ADsymptoms and flares, the concerns are more understandable.
Objective: This study aimed to investigate the safety of the coronavirus disease 2019 (COVID-19) vaccination in patients with AD treated with dupilumab.
Methods: We enrolled 133 patients (101 dupilumab-treated and 32 systemic oral agentstreatedas control group) with AD from six hospitals. Patients were asked about worseningpruritus and AD (5-point Likert scale) after vaccination. AD variables (eczema area and severityindex [EASI], investigator’s global assessment [IGA], itch numerical rating scale [NRS],sleep NRS, and patient-oriented eczema measure [POEM]) were compared pre- and postvaccination.
Adverse reactions to the COVID-19 vaccination were observed.
Results: The incidence of adverse reactions to COVID-19 vaccines and worsening ADsymptoms in dupilumab-treated patients were not significantly different compared with thatin the control group. The itch NRS score increased significantly after vaccination (p<0.001).
However, there were no statistically significant differences between the pre-and post-EASI,IGA, and POEM scores. Eight patients (7.9%) had worse EASI scores and required rescuetherapy; however, most were easily managed with low-dose steroids or topical agents. Noneof the patients discontinued dupilumab treatment.
Conclusion: No serious adverse reactions were observed in patients with AD after COVID-19 vaccination. Exacerbation of pruritus and AD symptoms was observed but wasmostly mild and transient.

참고문헌 (Reference)

1 Corbeddu M, "Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine : an Italian single-centre case series" 35 : e483-e485, 2021

2 Abuabara K, "The long-term course of atopic dermatitis" 35 : 291-297, 2017

3 Law JC, "Systematic examination of antigen-specific recall T cell responses to SARS-CoV-2 versus influenza virus reveals a distinct inflammatory profile" 206 : 37-50, 2021

4 Polack FP, "Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine" 383 : 2603-2615, 2020

5 Sadoff J, "Safety and efficacy of single-dose Ad26. COV2. S vaccine against COVID-19" 384 : 2187-2201, 2021

6 Ring J, "Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases-practical recommendations. A position statement of ETFAD with external experts" 35 : e362-e365, 2021

7 Chavda VP, "Replicating viral vector-based vaccines for COVID-19 : potential avenue in vaccination arena" 14 : 759-, 2022

8 Robert-Guroff M, "Replicating and non-replicating viral vectors for vaccine development" 18 : 546-556, 2007

9 Simonetti O, "Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic : a look into the past for a conscious vaccination management" 17 : 3268-3275, 2021

10 이동훈 ; 고현창 ; 나찬호 ; 노주영 ; 박귀영 ; 박영립 ; 박영민 ; 박창욱 ; 박천욱 ; 배유인 ; 서영준 ; 손상욱 ; 안지영 ; 정혜정 ; 양준모 ; 원종현 ; 유광호 ; 유박린 ; 이상은 ; 이성열 ; 이승철 ; 이양원 ; 이지현 ; 장용현 ; 전지현 ; 한태영 ; 조상현, "Real-World Experience of Long-Term Dupilumab Treatment for Atopic Dermatitis in Korea" 대한피부과학회 34 (34): 157-160, 2022

11 Martorell A, "Position document: IgE-mediated allergy to egg protein" 41 : 320-336, 2013

12 Leasure AC, "Generalized eczematous reactions to the Pfizer-BioNTech COVID-19 vaccine" 35 : e716-e717, 2021

13 Pakhchanian H, "Examining the risk of breakthrough infection and COVID-19 vaccination safety in patients with atopic dermatitis" 187 : 251-253, 2022

14 Thyssen JP, "European Task Force on Atopic Dermatitis : position on vaccination of adult patients with atopic dermatitis against COVID-19(SARS-CoV-2)being treated with systemic medication and biologics" 35 : e308-e311, 2021

15 Baden LR, "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine" 384 : 403-416, 2021

16 Reed JL, "Eczema vaccinatum" 54 : 832-840, 2012

17 Blauvelt A, "Dupilumab does not affect correlates of vaccine-induced immunity : a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis" 80 : 158-167, 2019

18 McMahon DE, "Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination : a registry-based study of 414 cases" 85 : 46-55, 2021

19 Català A, "Cutaneous reactions after SARS-CoV-2 vaccination : a cross-sectional Spanish nationwide study of 405 cases" 186 : 142-152, 2022

20 Gambichler T, "Cutaneous findings following COVID-19 vaccination : review of world literature and own experience" 36 : 172-180, 2022

21 Bellinato F, "Cutaneous adverse reactions associated with SARS-CoV-2 vaccines" 10 : 5344-, 2021

22 Sun Q, "COVID-19 vaccines and the skin : the landscape of cutaneous vaccine reactions worldwide" 39 : 653-673, 2021

23 Pfaar O, "COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy(biologicals)-a position paper of the German Society of Allergology and Clinical Immunology(DGAKI)and the German Society for Applied Allergology(AeDA)" 5 : 140-147, 2021

24 Potestio L, "Atopic dermatitis exacerbation after COVID-19 vaccination in Dupilumab-treated patients" 36 : e409-e411, 2022

25 Leung DYM, "A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis" 139 : 1575-1582, 2017